ABSCI CORPORATION ABSI 深 滬
等待開盤 10-09 09:30:00 美东时间
4.18
+0.440
+11.76%
華盛通- 最 高4.29
- 今 開3.76
- 成交量 866.82万股
- 最 低 3.65
- 昨 收 3.74
- 總市值 6.27亿
- 52周最高 6.33
- 市盈率 靜 --
- 換手率 5.78%
- 52周最低 2.01
- 委 比 -72.08%
- 總股本 1.50亿
- 歷史最高 31.53
- 量 比 1.08
- 振 幅 17.11%
- 歷史最低 1.1111
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
10-08 22:39
JP Morgan Initiates Coverage On Absci with Overweight Rating
JP Morgan analyst Brian Cheng initiates coverage on Absci (NASDAQ:ABSI) with a Overweight rating.
10-02 19:18
Absci(ABSI.US)携手甲骨文(ORCL.US)与AMD(AMD.US)，加速AI驱动的药物研发进程
Absci公司（ABSI.US）于周四宣布，将与甲骨文（ORCL.US）及AMD公司（AMD.US）展开合作，以加快其人工智能（AI）驱动的药物研发工作。
09-12 11:00
AI药物开发商Absci一度涨超21%，与甲骨文和AMD达成合作
人工智能药物开发商Absci(ABSI.US)盘初一度涨超21%，最高触及2.89美元。消息面上，Absci宣布，与甲骨文和AMD合作，加速生成式人工智能驱动的...
09-11 21:40
Absci shares are trading higher after the company announced it will use Oracle Cloud Infrastructure and AMD hardware for AI-driven drug discovery.
Absci shares are trading higher after the company announced it will use Oracle ...
09-11 20:03
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Absci collaborates with Oracle Cloud Infrastructure (OCI) and AMD to accelerate AI-driven drug discovery. Their partnership leverages OCI's AI infrastructure and AMD's GPUs, enhancing performance and scalability for biologics design, leading to faster therapeutic development and cost reduction.
09-11 12:00
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
Absci announced the addition of renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg to the ABS-201 Scientific Advisory Board. ABS-201, an AI-designed therapeutic antibody, targets prolactin receptors to stimulate hair follicle regeneration for treating androgenetic alopecia, with promising preclinical results. The Phase 1/2a trials are set to begin early 2026, with initial data expected later that year.
08-25 20:05
Absci to Participate in Upcoming Investor Conferences
Absci Corporation announced its participation in the 2025 Wells Fargo Healthcare Conference on September 3, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. The company will host fireside chats and one-on-one meetings at these events. Live and archived webcasts of the Morgan Stanley and H.C. Wainwright sessions can be accessed on the compan...
08-20 12:00
Needham Maintains Buy on Absci, Lowers Price Target to $8
Needham analyst Gil Blum maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $9 to $8.
08-13 18:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
